Survey of fractures after discontinuation of denosumab in patients with rheumatoid arthritis.

Survey of fractures after discontinuation of denosumab in patients with rheumatoid arthritis. - Survey of fractures after discontinuation of denosumab in patients with rheumatoid arthritis.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036972

Enrollment

194

Registered

2019-06-07

Start date

2019-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Preliminary survey 1.Patients who had been received denosumab for at least 1 year while participating in the DESIRABLE. 2.Outpatients who are visiting the same institution as they visited in DESIRABLE. 3.Patients who had a washout period of >7 months between denosumab doses by the date of the preliminary survey. 4.Patients who had not been diagnosed with osteoporosis by the day of 7 months after the last dose of denosumab.Regarding patients with multiple washout periods, ones who had not been diagnosed with osteoporosis by the 7 months after the last dose of denosumab about the first washout period. Main survey 1.Patients who can give voluntary written informed consent. 2.Patients with development of fracture in preliminary survey.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Number and details of fractures after denosumab discontinuation.	—

Countries

Japan

Contacts

Public ContactHideaki Sainomoto

Daiichi Sankyo RD Novare Co., Ltd Clinical Development

sainomoto.hideaki.mb@rdn.daiichisankyo.co.jp03-5436-8542

Outcome results